SCHEMBL6980439

SCHEMBL6980439

NCc1nc2ccccc2nc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.58
KDM4E B2RXH2 5/20 0.45
PKM P14618 1/20 0.45
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
NPSR1 Q6W5P4 2/20 0.40
UBE2T Q9NPD8 1/20 0.38
ASIC3 Q9UHC3 1/20 0.38
HTR3B O95264 1/20 0.37
HTR3A P46098 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
PNMT P11086 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20828787 0.78 TDP1 (0.58) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL681846 0.78 TDP1 (0.58) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL28196230 0.78 TDP1 (0.58) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL27888069 0.78 TDP1 (0.58) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL10009532 0.78 TDP1 (0.58) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL13425225 0.78 TDP1 (0.58) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL116696 0.75 TDP1 (1.00) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL29451077 0.75 TDP1 (1.00) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL24291302 0.75 TDP1 (0.54) TDP1KDM4EPKMMAPTKMT2A
SCHEMBL3611417 0.75 TDP1 (0.54) TDP1KDM4EPKMGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415353-B2 Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-04-09 US disclosed
WO-2012064897-A2 BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE CHEN YUAN (US) 2012-05-18 WO disclosed
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110105513-A1 AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 TDP1 4213/4885KDM4E 1897/4885PKM 4006/4885
US-20110105513-A1 AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 TDP1 804/4885KDM4E 3727/4885PKM 1854/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 TDP1 4213/4885KDM4E 1897/4885PKM 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.